Harvard Clinical and Translational Science Center

哈佛临床和转化科学中心

• 批准号: 8721090
• 负责人: Lee Marshall Nadler
• 金额: $ 60.52万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-26 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8721090
• 关键词: Achievement; Address; Biological Markers; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Commit; Communities; Coupled; Education; Environment; Future; Goals; Health; Healthcare; Home environment; Human; Human Experimentation; Incentives; Institution; Instruction; Investigation; Methodology; Participant; Pathway interactions; Patients; Prevention; Research Infrastructure; Research Personnel; Research Training; Resolution; Resources; Safety; Schools; Science; Services; Speed; Strategic Planning; Structure; Therapeutic; Training; Training and Education; Transcend; Translating; Translational Research; Vision; Work; career development; catalyst; cost; improved; innovation; medical schools

Harvard Catalyst has transcended the boundaries long imposed by the historical, corporate, and cultural independence of Harvard and its 17 affiliated academic healthcare centers (AHCs) to bring cross-disciplinary investigators together to collaborate and form teams to conduct clinical and translational (CT) research. Today education, resources and services are jointly planned, executed, broadly shared, and evaluated with the common goal of improving the quality, speed, safety, efficiency and cost across the entire spectrum of CT research. Ongoing CTSA recognition coupled with the opportunity to be a significant participant in the Consortium will enable Harvard Catalyst to implement its vision and strategic plan. First, we will convene investigators from our 11 schools and 17 AHCs to identify and prioritize the most important opportunities in CT research. We will help them to connect with one another to form cross-disciplinary teams and then provide them with the opportunities, incentives, and access to outstanding education and resources in an environment that values innovation, collaboration, and team science. Second, we will work with our schools and AHCs to build and grow an environment where discoveries are rapidly and efficiently translated to improve human health. Simply stated, Harvard Catalyst strives to be a Convener, Connector and Catalyst to hasten and improve the quality CT research. To this end, we have structured our academic home to create an integrated pathway of education, training, and career development and to provide a full portfolio of innovative resources and services to address identified gaps and investigator needs. Within five years, our achievements will include: 1) a continuous, sustainable, robust pipeline of future team leaders across all CT domains; 2) implementation of SHRINE-CT coupled with resolution of regulatory hurdles to allow investigators to rapidly identify, contact, and accrue specific patients to clinical trials across institutions and throughout the Consortium; 3) establishment of a team of experts who will reduce the barriers to engagement and entry to human experimentation thereby growing and diversifying the community of investigators who conduct CT research; 4) infrastructure to provide all CT investigators access to the resources they need to conduct human clinical studies wherever their work is best done; and 5) systematic investigation of innovative methodologies to incentivize, form and nurture teams to create new preventions, biomarkers, and therapeutics. These achievements will continue the transformation of CT research at Harvard with the goal of catalyzing a "One Harvard" community and culture committed to improving health. RELEVANCE (See instructions): The Harvard Clinical and Translational Science Center supports an academic home that creates an integrated research and training environment across Harvard Medical School and its partner institutions in order to improve human health. It provides and/or creates access to resources and services to support all steps of clinical research across the full spectrum of clinical and translational research, and facilitates the training and career development of the translational research workforce.

哈佛大学催化剂已经超越了历史，企业和文化的长期界限 哈佛的独立及其17个附属学术医疗中心（AHC）带来跨学科 研究人员共同进行合作并组建团队以进行临床和翻译（CT）研究。 今天，共同计划，执行，广泛共享和评估教育，资源和服务 在整个范围内提高质量，速度，安全性，效率和成本的共同目标 CT研究。持续的CTSA认可，加上有机会成为重要参与者 财团将使哈佛催化剂能够实施其愿景和战略计划。首先，我们将召集 来自我们11所学校和17名AHC的调查人员，以识别和优先考虑最重要的机会 CT研究。我们将帮助他们彼此建立跨学科团队，然后 为他们提供机会，激励措施，并获得杰出的教育和资源 重视创新，协作和团队科学的环境。其次，我们将与学校合作 和AHC建立和发展一个环境，发现发现迅速有效地转化为 改善人类健康。简而言之，哈佛催化剂努力成为召集人，连接器和催化剂 加快和改善质量CT研究。为此，我们已经为我们的学术住所构建了 创建一个综合的教育，培训和职业发展途径，并提供完整的组合 创新资源和服务以满足确定的差距和研究者需求。在五年之内，我们 成就将包括：1）所有CT中未来团队领导者的连续，可持续，强大的管道 域； 2）实施神社-CT，加上解决监管障碍的解决方案 调查人员迅速识别，接触和吸引特定患者， 整个财团； 3）建立一个专家团队，他们将减少障碍 参与和进入人类实验，从而成长和多元化的社区 进行CT研究的调查人员； 4）基础架构可为所有CT调查人员提供访问 他们需要进行人类临床研究所需的资源，无论他们在任何地方都可以完成工作； 5）系统 调查创新方法，以激励，形成和培养团队以创建新的预防措施， 生物标志物和治疗剂。这些成就将继续在CT研究的转变 哈佛的目标是催化致力于改善健康的“哈佛大学”社区和文化。 相关性（请参阅说明）： 哈佛临床和转化科学中心支持一个创造一个学术房屋 哈佛医学院及其合作伙伴机构的整合研究和培训环境 为了改善人类健康。它提供和/或创建对资源和服务的访问，以支持所有 在临床和转化研究的全部范围内的临床研究步骤，并促进 翻译研究人员的培训和职业发展。